// App-Quantinova.ai

P1-18-21 : Neratinib reduces HER2+/luminal B breast cancer stem cell activity and inhibits resistance by blocking efflux mechanisms

Researchers

Presenter

  • Nathan Hull

Principal Investigators

  • Robert Clarke

  • Nigel Bundred

Medical Centers

  • University of Manchester, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • ATP-binding cassette super-family G member 2

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Mitoxantrone

  • Paclitaxel

  • Neratinib

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved